Following earlier posts on the Bayer vs Union of India (UOI)/Cipla writ proceedings before the Delhi High Court, let me bring to your attention another fallacious argument advanced by Bayer where they attempt to label all generic drugs as “spurious” drugs. Bayer’s writ petition states that Cipla’s generic version of Sorafanib, purported to be sold under the brand name “Soranib” would amount to a “spurious drug” under Section 17B of The Drugs and Cosmetics Act, 1940. This section provides as […]

In our last post, we bemoaned the fact that the government was not taking the Bayer writ seriously enough. This apathy caused Dilip Shah, Secretary General of the Indian Pharmaceutical Alliance (IPA) to write a letter to the government, as below: (A similarly worded letter was addressed to Mr Ashok Kumar, Secretary, Department of Pharmaceuticals as well). To:Mr Naresh Dayal SecretaryDepartment of HealthMinistry of Health & Family WelfareNirman Bhawan, Room No. 149New Delhi 110 011 Dear Mr Dayal, Re: Delhi